Trials / Unknown
UnknownNCT02275663
Azacytidine Plus FLAG for Relapsed or Refractory AML
Phase 2 Study of 5 Days Azacytidine Priming Prior to Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor (G-CSF) Combination for Patients With Relapsed or Refractory AML
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (estimated)
- Sponsor
- King Fahad Medical City · Other Government
- Sex
- All
- Age
- 16 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this phase 2 study is to test the efficacy of azacytidine given prior to fludarabine, cytarabine, and G-CSF for the treatment of relapsed or refractory acute myeloid leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azacytidine | |
| DRUG | Fludarabine | |
| DRUG | Cytarabine | |
| DRUG | Filgrastim | G-CSF |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2017-10-01
- Completion
- 2018-10-01
- First posted
- 2014-10-27
- Last updated
- 2015-01-06
Locations
1 site across 1 country: Saudi Arabia
Source: ClinicalTrials.gov record NCT02275663. Inclusion in this directory is not an endorsement.